---
title: "Morgan Stanley: Gives HANSOH PHARMA a \"Buy\" rating with a target price of HKD 24"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/222761404.md"
description: "Morgan Stanley released a research report stating that it has given HANSOH PHARMA an \"Overweight\" rating, with a target price of HKD 24. HANSOH PHARMA announced that it has entered into a global exclusive licensing agreement with Merck, granting it global exclusive rights to develop, manufacture, and commercialize the preclinical oral small molecule GLP-1 receptor agonist HS-10535, involving an upfront payment of USD 112 million, as well as milestone payments and royalties based on product sales of up to USD 1.9 billion"
datetime: "2024-12-19T06:12:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/222761404.md)
  - [en](https://longbridge.com/en/news/222761404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/222761404.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/222761404.md) | [繁體中文](https://longbridge.com/zh-HK/news/222761404.md)


# Morgan Stanley: Gives HANSOH PHARMA a "Buy" rating with a target price of HKD 24

Morgan Stanley released a research report stating that it has given HANSOH PHARMA an "Overweight" rating, with a target price of HKD 24. HANSOH PHARMA announced that it has entered into a global exclusive licensing agreement with Merck, granting it global exclusive rights to develop, manufacture, and commercialize the preclinical oral small molecule GLP-1 receptor agonist HS-10535, involving an upfront payment of USD 112 million, as well as milestone payments and royalties based on product sales of up to USD 1.9 billion

### 相关股票

- [HANSOH PHARMA (03692.HK)](https://longbridge.com/zh-CN/quote/03692.HK.md)
- [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-CN/quote/NVO.US.md)
- [Merck (MRK.US)](https://longbridge.com/zh-CN/quote/MRK.US.md)
- [Morgan Stanley (MS.US)](https://longbridge.com/zh-CN/quote/MS.US.md)
- [THDB (600867.CN)](https://longbridge.com/zh-CN/quote/600867.CN.md)
- [HYBIO (300199.CN)](https://longbridge.com/zh-CN/quote/300199.CN.md)
- [Eli Lilly (LLY.US)](https://longbridge.com/zh-CN/quote/LLY.US.md)
- [AstraZeneca (AZN.US)](https://longbridge.com/zh-CN/quote/AZN.US.md)

## 相关资讯与研究

- [Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives](https://longbridge.com/zh-CN/news/281032561.md)
- [Hansoh Pharmaceutical Proposes HKD 0.20 Final Dividend for 2025](https://longbridge.com/zh-CN/news/280918766.md)
- [Baiyunshan Pharma Gets Approval for Carbocisteine Oral Solution's Registration in Macau](https://longbridge.com/zh-CN/news/281478355.md)
- [Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$38 From HK$37.87, Keeps at Neutral](https://longbridge.com/zh-CN/news/281164648.md)
- [08:33 ETInc. Names Interstate to Its 'Fastest-Growing in the Mid-Atlantic' List](https://longbridge.com/zh-CN/news/281524757.md)